Chitosan Hemostasis Technology
From Molecular Mechanism to Clinical Application
This whitepaper provides a systematic technical review of chitosan hemostatic materials for medical device R&D professionals, clinical procurement decision-makers, and regulatory compliance specialists.
Molecular Structure & Hemostasis Mechanism
Chitosan is a linear polysaccharide derived from chitin through alkaline deacetylation, with the chemical structure (1,4)-2-amino-2-deoxy-β-D-glucan. Its key distinguishing feature from all other hemostatic materials: the C2 primary amine group (-NH₂) on each glucose unit protonates to -NH₃⁺ at physiological pH, conferring abundant positive cationic charges along the molecular chain.
Core Hemostasis Mechanism — Three-Step Synergy
- Electrostatic Adsorption & RBC Aggregation: The abundant cationic positive charges on chitosan surface electrostatically attract sialic acid residues (negatively charged) on red blood cell membranes, driving rapid RBC aggregation at the wound surface to form a physical blood clot precursor.
- Platelet Activation & Aggregation: The cationic surface simultaneously promotes platelet adhesion, spreading, and degranulation, releasing ADP, thromboxane A₂ and other procoagulant mediators to amplify coagulation signals.
- Coagulation Cascade Independent: The above two physical mechanisms are completely independent of endogenous coagulation factors. This means chitosan maintains reliable hemostatic effectiveness in patients receiving anticoagulation therapy (warfarin, heparin, rivaroxaban, etc.).
This "physical hemostasis" mechanism is chitosan's core advantage over oxidized cellulose (dependent on Factor XII activation) and gelatin-based materials (platelet-dependent). In scenarios where kaolin or zeolite effectiveness is limited by patient coagulation disorders, chitosan's charge-driven hemostasis mechanism demonstrates irreplaceable clinical value.
Manufacturing Process
Ruten Medical uses high-purity chitin from deep-sea snow crab shells as starting material, processed through the following key manufacturing chain:
1. Alkaline Deacetylation
Heterogeneous deacetylation under strictly controlled temperature (80-100°C) and NaOH concentration (40-50%). In-line infrared spectroscopy monitors deacetylation progress to ensure DD reaches 85-95% target range. Post-reaction washing with deionized water to neutral pH.
2. Deep Purification
Sequential acidic dissolution (acetic acid), activated carbon decolorization, microfiltration (0.45μm), and ultrafiltration (100 kDa cutoff) to remove proteins, endotoxins, and low molecular weight oligosaccharide residues. Final endotoxin controlled at < 0.5 EU/mg, meeting USP standards.
Core Innovation: Electrospinning Film Technology
Traditional chitosan dressings use solution casting or freeze-drying, resulting in low specific surface area and porosity, limiting blood absorption capacity and ion release rate.
Compared to cast films, electrospun chitosan membranes offer:
- 10-50x increased specific surface area: Nanofiber network provides enormous blood contact interface
- Porosity ≥ 80%: Biomimetic ECM structure promotes cell migration and tissue regeneration
- Rapid wetting: Complete wetting within < 3 seconds of blood contact
- Mechanical flexibility: Can be bent, folded without fracturing, facilitating surgical handling
3. Crosslinking & Stabilization
Ionic crosslinking with Genipin or sodium tripolyphosphate (TPP) to enhance wet-state mechanical integrity and degradation controllability while preserving amino cationic charge activity.
4. Terminal Sterilization
Finished products sterilized with ethylene oxide (EO). Post-sterilization forced desorption for 7 days ensures EO residuals < 4 μg/g (well below ISO 10993-7 limit), as verified by zeta potential testing.
Performance Data
The following data is based on independent third-party laboratory testing of Ruten CT-Surgical series (DD=90%, Mw=200 kDa):
| Performance Metric | Test Method | Measured Value |
|---|---|---|
| In Vitro Clotting Time | Whole blood coagulation kinetics (n=30) | ≤ 30 seconds |
| Liquid Absorption Capacity | PBS buffer free absorption (37°C) | ≥ 10 g/g |
| Tensile Strength (Dry) | ASTM D882 thin film method | 8.5 ± 1.2 MPa |
| Elongation at Break | ASTM D882 | 45 ± 8% |
| Antibacterial Activity (S. aureus) | ISO 22196 plate count method | Inhibition ≥ 99% |
| In Vivo Degradation Time | SD rat subcutaneous implant model (n=12) | 8-12 weeks complete |
| Endotoxin Level | LAL assay, USP <85> | < 0.5 EU/mg |
| Zeta Potential (pH 7.4) | Dynamic light scattering (DLS) | +35 ± 5 mV |
Note: Data represents representative batch test results. Actual values are per CoA.
Clinical Application Review
Chitosan hemostatic materials have accumulated extensive clinical evidence in the following specialties:
Cardiovascular Surgery
In CABG and valve replacement surgeries, chitosan dressings control diffuse oozing. Since patients are routinely heparinized, chitosan's cationic mechanism excels.
Key References: Ann Thorac Surg, 2019; J Card Surg, 2021Hepatobiliary Surgery
Control in hepatectomy. Chitosan membranes conform tightly to surfaces for rapid hemostasis without increasing postoperative bile leak risk.
Key References: HPB (Oxford), 2020; World J Surg, 2022Spinal Surgery
Filling bone wounds and epidural spaces. Research shows 35% average reduction in blood loss and reduced drain retention time.
Key References: Spine J, 2021; Eur Spine J, 2023Oral & Maxillofacial Surgery
Post-extraction and implant surgery. Chitosan's antibacterial properties provide dual value: hemostasis + reduced infection risk.
Key References: J Oral Maxillofac Surg, 2020; Int J Oral Sci, 2022Otolaryngology (ENT)
Nasal packing after FESS. Its degradability avoids secondary trauma from removal, improving patient comfort.
Key References: Laryngoscope, 2021; Rhinology, 2023Competitive Material Comparison
Differentiation analysis of chitosan vs. oxidized cellulose, gelatin, and thrombin:
| Dimension | Chitosan | Oxidized Cellulose | Gelatin Sponge | Thrombin |
|---|---|---|---|---|
| Hemostasis Mechanism | Physical charge adsorption | Acidic Factor XII activation | Physical adsorption + platelets | Enzymatic fibrinogen catalysis |
| Anticoagulant Compatible | Yes ✓ | Limited | Limited | Yes ✓ |
| In Vivo Biodegradability | Complete (8-12 weeks) | Partial (4-8 weeks) | Complete (4-6 weeks) | Complete |
| Inherent Antibacterial | Yes ✓ (≥99%) | Acid inhibition only | No | No |
| Storage Conditions | Room temp (≤30°C) | Room temp | Room temp | Refrigerated (2-8°C) |
| Cost Level | Medium ($$) | Medium ($$) | Low ($) | High ($$$$) |
Chitosan's Unique Comprehensive Advantages
Only material meeting all four
Anticoagulant effective + fully biodegradable + inherent antibacterial + room temp storage.
Avoids local acidic damage
Neutral pH is more tissue-friendly than oxidized cellulose's acidic degradation products.
No animal-derived risk
Crustacean-derived with strictly controlled endotoxins, avoiding viral risk from human/bovine plasma.
Low swelling compression risk
Controllable swelling (within 150%) avoids nerve compression seen with gelatin sponges.
References & Further Reading
Disclaimer: This whitepaper is for technical reference only. Cited literature are third-party results and do not guarantee outcomes. Read IFU. Contact info@rutenmedical.com.
Download Full PDF Version
Get a printable PDF with all charts, data tables, and references. Ideal for training, compliance, and procurement justification.
PDF format · ~18 pages · 3.2 MB · Last updated: April 2026